Clinical Trial Update: Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM [Phase 1]

View source ↗

Summary

Provides an update on dosing strategies being explored in a Phase 1 trial of CART-EGFR-IL13Ra2 for recurrent glioblastoma, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• CART-EGFR-IL13Ra2

Snippet

Sponsor: University of Pennsylvania | Conditions: Recurrent Glioblastoma | Phase 1 | Status: RECRUITING